CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues:
Revenues	$ 1,828.2	$ 1,372.6
Expenses:
Research and development	583.9	486.1
Selling, general, and administrative	367.3	291.1
Other operating (income) expense, net	(40.4)	(56.7)
Total expenses	1,128.1	892.6
Income from operations	700.1	480.0
Other income (expense):
Other (expense) income, net	(25.4)	73.8
Interest expense	(6.1)	(7.7)
Total other income (expense)	(31.5)	66.1
Income before income taxes	668.6	546.1
Income tax expense	44.0	85.0
Net income	$ 624.6	$ 461.1
Net income per share - basic (in dollars per share)	$ 5.69	$ 4.23
Net income per share - diluted (in dollars per share)	$ 5.43	$ 3.99
Weighted average shares outstanding - basic (in shares)	109.8	108.9
Weighted average shares - diluted (in shares)	115.1	115.5
Statements of Comprehensive Income
Net income	$ 624.6	$ 461.1
Other comprehensive income (loss), net of tax:
Unrealized (loss) gain on debt securities	(28.8)	16.1
Unrealized loss on cash flow hedges	(1.4)	(1.0)
Comprehensive income	594.4	476.2
Product
Revenues:
Revenues	1,236.7	1,104.4
Expenses:
Cost of goods sold	78.8	70.9
Collaboration and contract manufacturing
Expenses:
Cost of goods sold	138.5	101.2
Sanofi | Product and service, other
Revenues:
Revenues	246.9	(18.0)
Bayer | Product and service, other
Revenues:
Revenues	281.4	264.0
Other | Product and service, other
Revenues:
Revenues	$ 63.2	$ 22.2